US stock insider trading | Organogenesis disclosed 8 insider transactions on March 3rd

K-LinePoet · 2026-03-27T03:10:03+00:00

On March 3, 2026, Organogenesis disclosed insider trading activity, with Director Gillheeney selling 91,300 shares on March 1. Additionally, several executives conducted stock sales on February 18 and March 1, with significant total amounts. Organogenesis is a company focused on regenerative medicine and advanced wound care.

K-LinePoet

2026-03-27 03:10:03

Abstract generation in progress

On March 3, 2026, Organogenesis (ORGO) disclosed 8 insider trading transactions. Director Gillheeney Gary S. sold 91,300 shares on March 1, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 3, 2026	Executive	Montecalvo Antonio S.	February 18, 2026	Sell	3,778	3.84	14,500
March 3, 2026	Executive	Cavorsi Robert	February 18, 2026	Sell	5,487	3.84	21,100
March 3, 2026	Executive	Francisco David	February 18, 2026	Sell	14,700	3.84	56,400
March 3, 2026	Executive	Bilbo Patrick	February 18, 2026	Sell	16,400	3.84	62,900
March 3, 2026	Director	Gillheeney Gary S.	February 18, 2026	Sell	91,300	3.84	350,600
March 3, 2026	Executive	Cavorsi Robert	March 1, 2026	Sell	700	3.21	2,247.00
March 3, 2026	Executive	Freedman Lori	February 18, 2026	Sell	14,400	3.84	55,300
March 3, 2026	Executive	Grow Brian	February 18, 2026	Sell	11,900	3.84	45,600
February 18, 2026	Executive	Cavorsi Robert	February 15, 2026	Sell	17,700	3.73	65,900
February 18, 2026	Director	Gillheeney Gary S.	February 15, 2026	Sell	271,400	3.73	1,012,300

【Company Information】

Organogenesis Holdings Inc. is a company based in Delaware. The company is a leading regenerative medicine firm that offers a portfolio of biologically active and acellular biomaterials products in advanced wound care and surgical biologics (including orthopedic and spinal). Organogenesis’ comprehensive product portfolio is designed to treat a variety of patients with repair and regeneration needs.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.